Tag: New schizophrenia drug shows promise in US clinical testing
New schizophrenia drug shows promise in US clinical testing
Acute psychosis in schizophrenic patients may soon be treated with a new drug, KarXT that has reported positive results from a placebo-controlled clinical trial. Karuna Therapeutics’ new drug combines xanomeline and trospium, new compounds designed to interact with muscarinic receptors […]